DEFA14A ·Filed Apr 27, 2026
Proxy solicitation materials
Actionable Insight • Neutral
Monitor the May 21, 2026 annual meeting for any unstated governance issues that may have prompted the omission. No trading impact expected from this administrative update.
Final — all horizons settled through T+60d
MAIA ▲ +4.84% at T+60d
NEUTRAL call +4.84% · α vs SPY +0.06% · entry $1.24 → $1.30
T+1d
+0.81%
call +0.81% · α +1.29%
$1.25
settled 6mo ago
T+5d
+12.10%
call +12.10% · α +11.70%
$1.39
settled 6mo ago
T+20d
+7.26%
call +7.26% · α +2.30%
$1.33
settled 5mo ago
T+60d
+4.84%
call +4.84% · α +0.06%
$1.30
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
MAIA Biotechnology filed an amendment to its definitive proxy statement to include previously omitted data on equity compensation plans as of December 31, 2025. The filing is administrative and does not introduce new governance or strategic changes.
Key Financial Metrics
Meeting
2026-05-21
Key Facts
- Filing is an amendment to the DEFA14A to add 'Securities Authorized for Issuance Under Equity Compensation Plans' table, which was inadvertently omitted.
- Data reflects equity plan status as of December 31, 2025: 25,964,601 shares issuable upon exercise of outstanding options with a weighted average exercise price of $2.05.
- 431,153 shares remain available for future issuance under approved equity plans; no shares available under unapproved plans.
- No changes to board structure, executive compensation, or shareholder proposals are indicated in this amendment.
Financial Impact
No immediate financial impact. Potential future dilution of up to 431,153 shares under existing plans.
dilutionshare_count
Risk Factors
- Future share dilution possible if remaining equity awards are granted and exercised.
- Governance oversight concern due to initial omission of required compensation plan data.
Market Snapshot
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001493152-26-019015 |
| Document: 0001493152-26-019015-index-headers.html | 0001493152-26-019015 |
| Document: 0001493152-26-019015-index.html | 0001493152-26-019015 |
| Document: 0001493152-26-019015.txt | 0001493152-26-019015 |
17 reports for MAIA
83% Hit rate @ T+60 Went positive at some point 10 of 11 best @ T+60▲ +16.94%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | EFFECT | $1.18 | awaiting T+60 | — | $1.18 (−0.42%) |
Oct 6, 2026 21d ago | 8-K | $1.19 | awaiting T+60 | — | $1.18 (−0.42%) |
Sep 25, 2026 4w ago | S-3 | $1.18 | awaiting T+60 | — | $1.18 (−0.42%) |
Sep 16, 2026 5w ago | Press Release | $1.40 | awaiting T+60 | — | $1.18 (−15.36%) |
Sep 15, 2026 6w ago | Press Release | $1.34 | awaiting T+60 | — | $1.18 (−11.57%) |
Sep 15, 2026 6w ago | Insider Cluster | $1.34 | awaiting T+60 | — | $1.18 (−11.57%) |
Jun 3, 2026 20w ago | Press Release | $1.43 $1.38 | ▼ −3.50% | ▼ −6.00% | $1.18 (−17.13%) |
Jun 2, 2026 21w ago | Insider Cluster | $1.35 $1.39 | ▲ +2.96% | ▲ +1.85% | $1.18 (−12.22%) |
May 19, 2026 23w ago | DEFA14A | $1.23 $1.34 | ▲ +8.94% | ▲ +2.65% | $1.18 (−3.66%) |
May 14, 2026 23w ago | 8-K | $1.26 $1.38 | ▲ +9.52% | ▲ +5.01% | $1.18 (−5.95%) |
Showing 10 of 17
US Market Status
Market Open — Closes in 57m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers